Projects
EFCCA PROJECTS DIGEST Newsletter #2 Issue
The second edition of our EFCCA PROJECTS DIGEST is now available! In this new issue, we present the latest updates on several of our 5 Horizon Europe projects. Enjoy the reading!
Download Newsletter: EFCCA PROJECTS DIGEST Issue #2 (November 2023)
Horizon Europe - FIBROTARGET
EFCCA is involved in an exciting new Horizon Europe project called FIBROTARGET. This project aims to validate novel immunotherapeutic targets against fibrosis in inflammatory bowel disease in order to obtain patients and regulatory approval for implementation of these novel noninvasive imaging modalities as diagnostic and prognostic tools for fibrotic IBD. This will allow vital future therapeutic...
Horizon Europe - miGut
We take great pleasure in informing you that EFCCA is one of the 12 partners coming from 9 countries of the consortium for the miGut-Health Project, which has been selected for European funding under the Horizon 2020 framework. This project will strive to empower people living with IBD by creating state-of-the-art strategies for early disease prediction, prevention, and health monitoring. This...
Horizon Europe - METHYLOMIC
The METHYLOMIC project will build on multiple previous cohort studies that confirmed epigenetic biomarkers (specifically DNA methylation) as the most stringent predictor of response to biological therapy, zooming in on CD. DNA methylation profiles in peripheral blood as biomarkers of response/deep remission for three approved biologicals in CD have been specifically discovered and validated....
Horizon Europe - GlycanTrigger
The GlycanTrigger project proposes a thorough and innovative approach to understand better the health-to-chronic inflammation transition occurring in patients with CD that will be translated into improved disease prediction and prevention. The project aims to do so by addressing how changes in glycosylation of the gut mucosa act as a primary event that dysregulates not only local mechanisms (...
Horizon Europe - GENEGUT
The GENEGUT project will transform the treatment of ileal CD by developing a first-in-class oral RNA-based therapy, tackling inflammation locally in the intestinal tissue, while avoiding systemic side effects.
Despite advances in new immune modulators and biological treatment, up to 30% of patients become non-responders. Besides, intestinal fibrosis is a significant challenge in Crohn’s...
Read EFCCA PROJECTS DIGEST Newsletter!
We are delighted to present to you the EFCCA PROJECTS DIGEST. This newsletter will include information regarding the 5 Horizon Europe projects, 2 Horizon 2020 projects, and other projects that EFCCA is presently engaged in. The PROJECTS DIGEST will be published every 2-3 months, and we trust it will serve as a valuable resource for delving deeper into our ongoing research...
World IBD Day 2023
IBD HAS NO AGE is an EFCCA campaign started in 2022 in order to raise awareness of how Inflammatory Bowel Disease (IBD) is impacting on the life of people aged 60 years and over. This year, for World IBD Day 2023 (19 May), we are launching a survey on people with IBD aged 60 years and over to investigate more on this topic with questions related to both quality of care and quality of...
Patient Preferences
WHAT DO IBD PATIENTS FIND IMPORTANT IN THEIR TREATMENT?
“What do you find important in your (IBD?) treatment?”, “Which quality of life effects are important to you?”, “Which side-effects do you want to avoid?”, “Which characteristics should future drugs have according to you?”
To address these questions, EFCCA has embarked on exciting research with the University of Leuven (KU...
Horizon 2020- IDEA- FAST
EFCCA is involved in this exciting project that will identify digital endpoints that provide reliable, objective and sensitive evaluation of activities of daily living and Health-related quality of life (HRQoL) in ImmuneMediated Inflammatory Diseases such as IBD as well as other such as Rheumatoid Arthritis and Lupus and which will ultimately have a positive impact on the quality of life of these...